Bank of New York Mellon
MRVI icon

Bank of New York Mellon’s Maravai LifeSciences MRVI Stock Holding History

Bank of New York Mellon’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23M Buy
357,349
+13,706
+4% +$59.2K ﹤0.01% 2890
2026
Q1 		$973K Buy
343,643
+8,955
+3% +$30.4K ﹤0.01% 3226
2025
Q4 		$1.09M Sell
334,688
-3,214
-1% -$10.8K ﹤0.01% 3185
2025
Q3 		$970K Sell
337,902
-9,327
-3% -$23.8K ﹤0.01% 3227
2025
Q2 		$837K Buy
347,229
+52,982
+18% +$111K ﹤0.01% 3223
2025
Q1 		$650K Sell
294,247
-21,047
-7% -$83.2K ﹤0.01% 3317
2024
Q4 		$1.72M Sell
315,294
-83,940
-21% -$540K ﹤0.01% 2828
2024
Q3 		$3.32M Sell
399,234
-107,179
-21% -$926K ﹤0.01% 2507
2024
Q2 		$3.63M Buy
506,413
+117,120
+30% +$1.01M ﹤0.01% 2488
2024
Q1 		$3.38M Sell
389,293
-19,499
-5% -$132K ﹤0.01% 2507
2023
Q4 		$2.68M Sell
408,792
-106,331
-21% -$687K ﹤0.01% 2683
2023
Q3 		$5.15M Buy
515,123
+9,592
+2% +$105K ﹤0.01% 2302
2023
Q2 		$6.28M Sell
505,531
-99,718
-16% -$1.35M ﹤0.01% 2199
2023
Q1 		$8.48M Buy
605,249
+6,951
+1% +$99.8K ﹤0.01% 2011
2022
Q4 		$8.56M Buy
598,298
+47,122
+9% +$742K ﹤0.01% 2020
2022
Q3 		$14.1M Sell
551,176
-37,361
-6% -$937K ﹤0.01% 1695
2022
Q2 		$16.7M Buy
588,537
+171,920
+41% +$5.45M ﹤0.01% 1638
2022
Q1 		$14.7M Buy
416,617
+6,339
+2% +$213K ﹤0.01% 1858
2021
Q4 		$17.2M Buy
410,278
+49,562
+14% +$2.01M ﹤0.01% 1813
2021
Q3 		$17.7M Buy
360,716
+87,254
+32% +$4.26M ﹤0.01% 1796
2021
Q2 		$11.4M Buy
273,462
+111,832
+69% +$4.33M ﹤0.01% 2060
2021
Q1 		$5.76M Buy
+161,630
New +$5.35M ﹤0.01% 2380

Other funds holding MRVI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return
GAI
General American Investors New York $1.69B AUM 40.94% 1-Year Est. Return

Bank of New York Mellon's MRVI Position: Q2 2026 in Review

Bank of New York Mellon increased its Maravai LifeSciences (MRVI) stake by 4% in Q2 2026, buying an estimated $59.2K and bringing the position to 357,349 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2890.

Bank of New York Mellon first reported a position in MRVI in Q1 2021 and has held it in 22 quarters since. The position peaked at $17.7M in Q3 2021. 86 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • Bank of New York Mellon held 357,349 shares of Maravai LifeSciences worth $2.23M as of Q2 2026.
  • Bank of New York Mellon bought 13,706 Maravai LifeSciences shares in Q2 2026, an estimated $59.2K.
  • Maravai LifeSciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2890 holding.
  • Bank of New York Mellon first reported a position in Maravai LifeSciences in Q1 2021 and has held it in 22 quarters since.
  • Bank of New York Mellon's Maravai LifeSciences position peaked at $17.7M in Q3 2021.
  • 86 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.